Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes

References

• Adida E (2021) Outcome-based pricing for new pharmaceuticals via rebates. Management Sci. 67(2):892–913.Link, Google Scholar
• Adida E, Bravo F (2019) Contracts for healthcare referral services: Coordination via outcome-based penalty contracts. Management Sci. 65(3):1322–1341.Link, Google Scholar
• Adida E, Dey D, Mamani H (2013) Operational issues and network effects in vaccine markets. Eur. J. Oper. Res. 231(2):414–427.Crossref, Google Scholar
• Akkaya D, Bimpikis K, Lee H (2021) Government interventions to promote agricultural innovation. Manufacturing Service Oper. Management 23(2):437–452.Abstract, Google Scholar
• Alizamir S, Iravani F, Mamani H (2019) An analysis of price vs. revenue protection: Government subsidies in the agriculture industry. Management Sci. 65(1):32–49.Link, Google Scholar
• Andritsos DA, Tang CS (2018) Incentive programs for reducing readmissions when patient care is co-produced. Production Oper. Management 27(6):999–1020.Crossref, Google Scholar
• Barberis N, Huang M (2001) Mental accounting, loss aversion, and individual stock returns. J. Finance 56(4):1247–1292.Crossref, Google Scholar
• Barros PP (2011) The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econom. 20(4):461–470.Crossref, Google Scholar
• Beneluxa (2018) Pilots on joint HTA (Health Technology Assessment) and joint negotiations. Accessed November 15, 2021, https://beneluxa.org/index.php/pricing.Google Scholar
• Betcheva L, Erhun F, Jiang H (2021) Supply chain thinking in healthcare: Lessons and outlooks. Manufacturing Service Oper. Management 23(6):1333–1682.Link, Google Scholar
• CADTH (2019) Pharmacoeconomic review report (resubmission): NUSINERSEN (SPINRAZA): (Biogen Canada Inc.): Indication: Treatment of patients with 5q spinal muscular atrophy. Accessed November 15, 2021, https://www.ncbi.nlm.nih.gov/books/NBK542538/.Google Scholar
• Chick SE, Mamani H, Simchi-Levi D (2008) Supply chain coordination and influenza vaccination. Oper. Res. 56(6):1493–1506.Link, Google Scholar
• Cohen J (2017) Orphan drug pricing and reimbursement: Challenges to patient access. Accessed November 15, 2021, https://invivo.pharmaintelligence.informa.com/IV005214/Orphan-Drug-Pricing-And-Reimbursement-Challenges-To-Patient-Access.Google Scholar
• Cohen MC, Lobel R, Perakis G (2016) The impact of demand uncertainty on consumer subsidies for green technology adoption. Management Sci. 62(5):1235–1258.Link, Google Scholar
• Cure SMA (2019) Biogen issues community statement on Spinraza. Accessed November 15, 2021, https://www.curesma.org/biogen-community-statement-aug2019/.Google Scholar
• Dai T, Tayur S (2020) OM forum—Healthcare operations management: A snapshot of emerging research. Manufacturing Service Oper. Management 22(5):869–887.Link, Google Scholar
• Elvidge S (2017) Another US insurer places limits on Spinraza coverage. Accessed November 15, 2021, https://www.biopharmadive.com/news/humana-spinraza-coverage-insurer-biogen/435923/.Google Scholar
• EMA (2015) Orphan medicinal product designation. Accessed November 15, 2021, https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview.Google Scholar
• EMA (2017) EPAR summary for the public: Spinraza. Accessed November 15, 2021, https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza.Google Scholar
• EMA (2021) Orphan incentives. Accessed November 15, 2021, https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives.Google Scholar
• European Commission (2020) Joint evaluation of regulation (EC) No 1901/2006 of the European parliament. Accessed November 15, 2021, https://www.europa-nu.nl/id/vlbp6n95ckys/commission_staff_working_document.Google Scholar
• EvaluatePharma (2013) Orphan drug report 2013. Accessed November 15, 2021, https://info.evaluategroup.com/OrphanDrug2013_MSC_LP.html.Google Scholar
• EvaluatePharma (2019) Orphan drug report 2019. Accessed November 15, 2021, https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019.Google Scholar
• Faulkner S, Lee M, Qin D, Morrell L, Xoxi E, Sammarco A, Cammarata S, et al. (2016) Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. Clinical Pharmacological Therapy 100(6):730–742.Crossref, Google Scholar
• FDA (2017) About orphan products clinical trials grants. Accessed November 15, 2021, https://www.fda.gov/industry/developing-products-rare-diseases-conditions/about-orphan-products-clinical-trial-grants.Google Scholar
• Fuloria PC, Zenios SA (2001) Outcomes-adjusted reimbursement in a health-care delivery system. Management Sci. 47(6):735–751.Link, Google Scholar
• Galizzi MM, Miraldo M, Stavropoulou C, Van Der Pol M (2016) Doctor–patient differences in risk and time preferences: A field experiment. J. Health Econom. 50:171–182.Crossref, Google Scholar
• Gupta Strategists (2019) The cost of opportunity: A study on pharmaceutical R&D costs. Accessed November 15, 2021, https://gupta-strategists.nl/storage/files/The-cost-of-opportunity-Gupta-Strategists.pdf.Google Scholar
• Hagenacker T, Wurster CD, Günther R, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, et al. (2020) Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurology 19(4):317–325.Crossref, Google Scholar
• Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nature Biotech. 32(1):40–51.Crossref, Google Scholar
• Henrard S, Arickx F (2016) Negotiating prices of drugs for rare diseases. Bull. World Health Organ. 94(10):779.Crossref, Google Scholar
• Horvath C (2010) Comparison of preclinical development programs for small molecules (drugs/pharmaceuticals) and large molecules (biologics/biopharmaceuticals): Studies, timing, materials, and costs. Cavagnaro JA, ed. Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing (John Wiley & Sons, Inc., Hoboken, NJ), 1–35.Google Scholar
• IFPMA (2017) Leaving no-one behind: A set of policy principles to meet the global challenge of rare diseases. Accessed November 15, 2021, https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA_Rare_Diseases_Policy_Principles_28Feb2017_FINAL.pdf.Google Scholar
• IQVIA (2018) Orphan drugs in the United States: Growth trends in rare disease treatments. Accessed November 15, 2021, https://www.iqvia.com/insights/the-iqvia-institute/reports/orphan-drugs-in-the-united-states-growth-trends-in-rare-disease-treatments.Google Scholar
• Kahneman D, Tversky A (2013) Choices, values, and frames. Handbook of the Fundamentals of Financial Decision Making: Part I (World Scientific), 269–278.Crossref, Google Scholar
• Levi R, Perakis G, Romero G (2017) On the effectiveness of uniform subsidies in increasing market consumption. Management Sci. 63(1):40–57.Link, Google Scholar
• Luxner L (2018) SMA groups outraged over UK rejection of Spinraza coverage as too expensive. Accessed November 15, 2021, https://smanewstoday.com/news-posts/2018/08/16/sma-groups-outraged-over-uk-rejection-of-spinraza-coverage/.Google Scholar
• Luxner L (2019) In UK and Ireland, SMA patients demand reimbursement for Spinraza. Accessed November 15, 2021, https://smanewstoday.com/news-posts/2019/03/06/in-uk-and-ireland-sma-patients-demand-reimbursement-for-spinraza/.Google Scholar
• Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JC, et al. (2018) Outrageous prices of orphan drugs: A call for collaboration. Lancet 392(10149):791–794.Crossref, Google Scholar
• Mahjoub R, Ødegaard F, Zaric GS (2018) Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Econom. 27(1):15–25.Crossref, Google Scholar
• Malinowski KP, Kawalec P, Trabka W, Sowada C, Pilc A (2018) Reimbursement of orphan drugs in Europe in relation to the type of authorization by the European medicines agency and the decision making based on health technology assessment. Frontiers Pharmacology 9:1263.Crossref, Google Scholar
• Mamani H, Adida E, Dey D (2012) Vaccine market coordination using subsidy. IIE Trans. Healthcare Systems Engrg. 2(1):78–96.Crossref, Google Scholar
• McConaghie (2018) Beneluxa: The future of European market access? Accessed November 15, 2021, http://www.pmlive.com/blogs/smart_thinking/archive/2018/november/beneluxa_the_future_of_european_market_access.Google Scholar
• Medscape (2019) “No cure, no pay” pilot for expensive cancer drugs. Accessed November 15, 2021, https://www.medscape.com/viewarticle/915602.Google Scholar
• Meyer H (2019) As a cure for high drug prices, outcomes-based deals aren’t delivering yet. Accessed November 15, 2021, https://www.modernhealthcare.com/insurance/cure-high-drug-prices-outcomes-based-deals-arent-delivering-yet.Google Scholar
• Neurology L (2017) Treating rare disorders: Time to act on unfair prices. Lancet Neurology 16:761.Crossref, Google Scholar
• Rasiel EB, Weinfurt KP, Schulman KA (2005) Can prospect theory explain risk-seeking behavior by terminally ill patients? Medical Decision Making 25(6):609–613.Crossref, Google Scholar
• Rijksoverheid (2018) Positive outcome of joint reimbursement negotiations on Spinraza. Accessed November 15, 2021, https://beneluxa.org/archive#toc-12-july-2018-positive-outcome-of-joint-reimbursement-negotiations-on-spinraza.Google Scholar
• Ring E (2019) Somebody is going to die untreated in Ireland. Accessed November 15, 2021, https://www.irishexaminer.com/breakingnews/ireland/somebody-is-going-to-die-untreated-in-ireland-families-protest-for-spinraza-drug-to-be-made-available-907821.html.Google Scholar
• So KC, Tang CS (2000) Modeling the impact of an outcome-oriented reimbursement policy on clinic, patients, and pharmaceutical firms. Management Sci. 46(7):875–892.Link, Google Scholar
• Stiggelbout AM, Kiebert GM, Kievit J, Leer JWH, Stoter G, De Haes J (1994) Utility assessment in cancer patients: Adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Medical Decision Making 14(1):82–90.Crossref, Google Scholar
• Sutton E (2019) Joint pricing and health technology assessment between European countries: Is this the future of pricing and market access negotiations? Accessed November 15, 2021, https://remapconsulting.com/joint-pricing-and-health-technology-assessment-between-european-countries-is-this-the-future-of-pricing-and-market-access-negotiations/.Google Scholar
• Taylor TA, Xiao W (2014) Subsidizing the distribution channel: Donor funding to improve the availability of malaria drugs. Management Sci. 60(10):2461–2477.Link, Google Scholar
• Tversky A, Kahneman D (1989) Rational choice and the framing of decisions. Multiple Criteria Decision Making and Risk Analysis Using Microcomputers (Springer, Berlin), 81–126.Crossref, Google Scholar
• Vogler S, Haasis MA, Dedet G, Lam J, Bak Pedersen H (2018) Medicines Reimbursement Policies in Europe (WHO Regional Office for Europe).Google Scholar
• Xu L, Li H, Zhao H (2022) Outcome-based reimbursement: The solution to high drug spending? Manufacturing Service Oper. Management 24(4):2029–2047.Link, Google Scholar
• Yu JJ, Tang CS, Shen ZJM (2018) Improving consumer welfare and manufacturer profit via government subsidy programs: Subsidizing consumers or manufacturers? Manufacturing Service Oper. Management 20(4):752–766.Link, Google Scholar
• Yu JJ, Tang CS, Sodhi MS, Knuckles J (2020) Optimal subsidies for development supply chains. Manufacturing Service Oper. Management 22(6):1131–1147.Link, Google Scholar
• Zamora B, Maignen F, O’Neill P, Mestre-Ferrandiz J, Garau M (2019) Comparing access to orphan medicinal products in Europe. Orphanet J. Rare Diseases 14(1):1–12.Crossref, Google Scholar
• Zaric GS, Xie B (2009) The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value Health 12(5):838–845.Crossref, Google Scholar